SCHEMBL6827646

SCHEMBL6827646

CCOC(=O)C(CCCCNC(=O)OCc1ccccc1)C(=O)OCC

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.59
FOLH1 Q04609 5/20 0.57
TGM2 P21980 1/20 0.56
DPP8 Q6V1X1 1/20 0.55
DPP7 Q9UHL4 1/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.54
SIRT1 Q96EB6 1/20 0.54
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54
ANPEP P15144 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823763 0.96 FOLH1 (0.58) HTTFOLH1TGM2DPP8DPP7
SCHEMBL30214739 0.91 L3MBTL1 (0.59) HTTFOLH1TGM2LMNASMN1; SMN2
SCHEMBL11758185 0.89 HTT (0.58) HTTFOLH1TGM2DPP8DPP7
SCHEMBL10917494 0.88 DPP8 (0.64) HTTFOLH1TGM2DPP8DPP7
SCHEMBL10562902 0.88 HTT (0.56) HTTFOLH1TGM2DPP8DPP7
SCHEMBL23542526 0.88 DPP8 (0.64) HTTFOLH1TGM2DPP8DPP7
Hydrochloric Acid SCHEMBL11023028 0.86 DPP8 (0.63) HTTFOLH1TGM2DPP8DPP7
Hydrochloric Acid SCHEMBL27139143 0.86 DPP8 (0.63) HTTFOLH1TGM2DPP8DPP7
SCHEMBL31357186 0.85 HTT (0.54) HTTFOLH1TGM2DPP8DPP7
SCHEMBL29045163 0.85 HTT (0.63) HTTFOLH1TGM2DPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6737416-B2 THROMBOLYTIC AGENT HAVING HIGHER SAFETY MEIJI SEIKA KAISHA LTD. (JP) 2004-05-18 US disclosed
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2003-06-26 US disclosed
US-6576627-B1 Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease MEIJI SEIKA KAISHA LTD. (JP) 2003-06-10 US disclosed
EP-1152004-B1 Phosphonic acid derivatives having carboxypeptidase B inhibitory action MEIJI SEIKA KAISHA (JP) 2003-05-07 EP disclosed
EP-1174434-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2002-01-23 EP disclosed
EP-1152004-A1 PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY MEIJI SEIKA KAISHA LTD. (JP) 2001-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B CPB1, RNPEP, CPN1 HTT 3437/4885FOLH1 73/4885TGM2 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.